Study on the efficacy and safety of tiotropium bromide inhalation agent with tulobuterol patch in the treat- ment of C and D level in patients with chronic obstructive pulmonary disease in stable period
10.3760/cma.j.issn.1008-6706.2015.05.022
- VernacularTitle:吸入噻托溴铵干粉剂联合妥洛特罗贴剂治疗C、D级慢性阻塞性肺疾病稳定期的疗效与安全性
- Author:
Yu ZHOU
;
Shihua WU
;
Haohai ZHONG
;
Zhonghong CHEN
;
Huiqing SU
;
Zhongzhi ZHOU
- Publication Type:Journal Article
- Keywords:
Pulmonary Disease,Chronic Obstructive;
Pulmonary function;
Tiotropium bromide;
Tulobuterol
- From:
Chinese Journal of Primary Medicine and Pharmacy
2015;(5):705-708
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the effectiveness and safety of tiotropium bromide inhalation agent with tulobuterol patch in the treatment of C and D level of COPD in stable period .Methods According to the digital table,255 cases of C and D level in patients with stable COPD were randomly divided into the study group and control group,the patients in study group received inhalation of tiotropium bromide dry powder 18μg/times,one time every day,and give tulobuterol patch(2mg/paste),one time every day.The control group received inhalation of tiotropium bromide dry powder 18μg/times,one time every day.The changes of lung function were observed before and after treatment,the clinical symptom score and inhaled short acting beta 2 agonists used,6min walk test,times of acute exacerbation condition.Results The patients in the two groups after treatment ,pulmonary function ,clinical symptoms score,inhaled short acting beta 2 agonists used,6min walk test,times of acute exacerbation compared with statistical significance(all P<0.05).Subgroup analysis in study group ,emphysema phenotype visible persistent effect ,chronic bronchitis phenotype ,ACOS phenotype early effective treatment ,decreased efficacy after half a year .The adverse reac-tion of two groups of drugs were respectively 19.7%and 21.0%,there was no significant difference in the incidence of adverse reaction between the two groups (χ2 =0.071,P>0.05).Conclusion Tiotropium bromide inhalation agent with tulobuterol patch can improve clinical symptoms and pulmonary function in patients with C and D level part of the stable phase of COPD .
